Evidence map›Paper›PMID 26634699›Full record

ArticleBMC veterinary research2015

Effect of Cyclooxygenase(COX)-1 and COX-2 inhibition on furosemide-induced renal responses and isoform immunolocalization in the healthy cat kidney.

L Pelligand, N Suemanotham, J N King, W Seewald, H Syme, K Smith, P Lees, J Elliott

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Reply to the Commentary: Should Injectable Meloxicam Be Approved for Use in Cats?Journal of veterinary pharmacology and therapeutics · 2026
    Article
  2. Article
  3. Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib.Journal of veterinary pharmacology and therapeutics · 2022
    Review
  4. Article
  5. The profile of urinary lipid metabolites in cats.The Journal of veterinary medical science · 2020
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

L PelligandDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK. lpelligand@rvc.ac.uk.
N SuemanothamFaculty of Veterinary Science, Mahidol University, Nakhon Pathom, Thailand. phungcud35@hotmail.com.
J N KingNovartis Animal Health Inc., Clinical Development, Basel, Switzerland. jonathan.king@novartis.com.
W SeewaldNovartis Animal Health Inc., Clinical Development, Basel, Switzerland. wolfgang.seewald@novartis.com.
H SymeDepartment of Clinical Sciences and Services, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK. hsyme@rvc.ac.uk.
K SmithDepartment of Pathology and Pathogen Biology, The Royal Veterinary College, Hawkshead Lane, North Mymms, Hatfield, AL9 7TA, Hertfordshire, UK. ksmith@rvc.ac.uk.
P LeesDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK. plees@rvc.ac.uk.
J ElliottDepartment of Comparative Biomedical Sciences, The Royal Veterinary College, Royal College Street, London, NW1 0TU, UK. jelliott@rvc.ac.uk.
Royal Veterinary College · GBNovartis (Switzerland) · CHMahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of cyclooxygenase(COX)-1 and COX-2 in the saluretic and renin-angiotensin responses to loop diuretics in the cat is unknown. We propose in vivo characterisation of isoform roles in a furosemide model by administering non-steroidal anti-inflammatory drugs (NSAIDs) with differing selectivity profiles: robenacoxib (COX-2 selective) and ketoprofen (COX-1 selective).

resultsIn this four period crossover study, we compared the effect of four treatments: placebo, robenacoxib once or twice daily and ketoprofen once daily concomitantly with furosemide in seven healthy cats. For each period, urine and blood samples were collected at baseline and within 48 h of treatment starting. Plasma renin activity (PRA), plasma and urinary aldosterone concentrations, glomerular filtration rate (GFR) and 24 h urinary volumes, electrolytes and eicosanoids (PGE2, 6-keto-PGF1α, TxB2), renal injury biomarker excretions [N-acetyl-beta-D-glucosaminidase (NAG) and Gamma-Glutamyltransferase] were measured. Urine volume (24 h) and urinary sodium, chloride and calcium excretions increased from baseline with all treatments. Plasma creatinine increased with all treatments except placebo, whereas GFR was significantly decreased from baseline only with ketoprofen. PRA increased significantly with placebo and once daily robenacoxib and the increase was significantly higher with placebo compared to ketoprofen (10.5 ± 4.4 vs 4.9 ± 5.0 ng ml(-1) h(-1)). Urinary aldosterone excretion increased with all treatments but this increase was inhibited by 75 % with ketoprofen and 65 % with once daily robenacoxib compared to placebo. Urinary PGE2 excretion decreased with all treatments and excretion was significantly lower with ketoprofen compared to placebo. Urinary TxB2 excretion was significantly increased from baseline only with placebo. NAG increased from baseline with all treatments. Immunohistochemistry on post-mortem renal specimens, obtained from a different group of cats that died naturally of non-renal causes, suggested constitutive COX-1 and COX-2 co-localization in many renal structures including the macula densa (MD).

conclusionsThese data suggest that both COX-1 and COX-2 could generate the signal from the MD to the renin secreting cells in cats exposed to furosemide. Co-localization of COX isoenzymes in MD cells supports the functional data reported here.

Indexed as

AnimalsCatsCross-Over StudiesCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsDiphenylamineEicosanoidsFurosemideGene Expression Regulation, EnzymologicGlomerular Filtration RateKetoprofenKidneyPhenylacetatesProtein IsoformsProtein TransportCyclooxygenase 1Cyclooxygenase 2Cyclooxygenase InhibitorsDiphenylamineEicosanoidsFurosemideKetoprofenPhenylacetatesProtein IsoformsReninrobenacoxib

Identifiers

PMID26634699
PMCPMC4669647
OpenAlexW2185701329

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.